Mapping a Type-specific Epitope by Monoclonal Antibody against VP3 Protein of Duck Hepatitis A Type 1 Virus

Xiaoying Wu, Tingting Zhang, Fanyi Meng, Dongchun Guo, Xiuchen Yin, Shaozhou Wulin, Chenxi Li, Qingshan Zhang, Ming Liu & Yun Zhang

Duck hepatitis A subtype 1 virus (DHAV-1) infection causes high mortality in ducklings, resulting in significant losses to duck industries. VP3 is a structural protein of DHAV-1. However, B-cell epitopes on VP3 have not been investigated. To stimulate VP3 antibody response, eukaryotic expression plasmid pCI-neo-VP3 was constructed and used as DNA immunogen to prepare mAbs. Western blot showed that 25.5 kDa VP3 could be detected by mAbs in duck embryo fibroblast (DEF) cells transfected with pCI-neo-VP3. Immunofluorescence assay showed that mAbs could specifically bind to DEF cells infected with DHAV-1. DAPI staining indicated that VP3 localizes to the cytoplasm and nucleus of DHAV-1 infected DEF. With neutralizing mAb 3B7, minimal epitope PSNI was mapped. Sequence alignment indicated that 205PSNI208 is highly conserved among DHAV-1, but different from those of DHAV-2 and DHAV-3. Epitope peptide reacted specifically with DHAV-1-positive duck sera by dot blotting, revealing PSNI is DHAV-1 type-specific epitope and the importance of these amino acids in antibody-epitope binding reactivity. These findings provided useful information for understanding the antigenicity of VP3 and might be valuable in the development of epitope-based vaccine or diagnostic kit for DHAV-1 infection and provide insights for understanding the pathogenesis of DHAV-1.
only express protein faithfully, but also induce strong specific immune responses in animals. Thus, a eukaryotic expression plasmid (pCI-neo-VP3) was constructed and used as DNA immunogen to prepare mAbs in mice and then the epitope of VP3 was identified. Sequence analysis and immunological assay confirmed that this epitope is DHAV-1 type specific and would be useful in development epitope-based diagnostic kit for DHAV-1 infections.

Results

pCI-neo-VP3 construction and VP3 sequence analysis. The 712 bp VP3-encoding gene was amplified and cloned into pCI-neo vector. To confirm the recombinant plasmids were correct, pCI-neo-VP3 were digested by Xho I and Sma I restriction analysis and then for nucleotide sequencing. Electrophoresis results revealed that pCI-neo-VP3 plasmids were digested into two fragments, which were consistent with sizes of VP3-encoding gene and pCI-neo vector, respectively (Supplementary Figure S1). Sequencing results confirmed that VP3-encoding gene was successfully cloned into pCI-neo vector. The predicted 237 amino acids of the VP3 protein showed a molecular mass of about 26 kDa. There are three common potential glycosylation sites (NLS34, NSS37, and NSS202) (Supplementary Figure S2). Amino acid sequences of VP3 screen reveals that there is a motif rich in basic amino acids (GKRKPRPHKPKKN) (eight basic amino acids underlined), which located at the N-terminal region.

mAbs production and characterization. After cell fusion, the hybridoma cell lines secreting anti-VP3 antibody were screened by ELISA. Three mAbs directed against VP3 were selected for subcloning at least three times. The mAbs were produced and designed as 3B7, 4F8, and 3E9. Hybridomas were selected to produce mAbs in mice, and the ascetic fluids were used for further characterization. The isotypes of the mAbs were IgG1 (3B7) and IgM (4F8 and 3E9). Concentrations of immunoglobulin ranged from 0.71 to 15.83 µg/ml. The neutralization test showed that 3B7 neutralized the DHAV-1 HP1 virus with a neutralization titer of 16. 4F8 and 3E9 did not show any neutralizing activity.

VP3 protein detection by Western blot. To prove VP3 expressed in pCI-neo-VP3 transfected DEF cells, duck anti-DHAV-1 sera were used first to detect VP3 protein by Western blot. Representative Fig. 1a showed that duck anti-DHAV-1 sera could react with 26 kDa VP3 protein in pCI-neo-VP3 transfected DEF cells, whereas pCI-neo transfected DEF cells did show any reaction to duck anti-DHAV-1 sera. pCI-neo-VP3 transfected DEF cells were then used to assess whether the obtained mAbs recognize the eukaryotic expressed VP3 protein by Western blot. Representative Fig. 1b demonstrated that three mAbs strong reacted with 26 kDa VP3 proteins in pCI-neo-VP3 transfected DEF cells, whereas pCI-neo transfected DEF cells did not show any neutralizing activity.

Detection of native VP3 protein by immunofluorescence assay. An immunofluorescence assay (IFA) was performed on DHAV-1 HP-1/DHAV-3 JT infected DEF to assess whether the produced mAbs recognize the native-form of VP3 protein. Three mAbs strongly reacted with HP-1-infected DEF cells, whereas DHAV-3 JT infected or uninfected DEF cells showed no reaction (represented by Fig. 2). DAPI staining indicated that the VP3 was located in the cytoplasm and nucleus of the DHAV-1 infected DEF cells.

Epitope Prediction. To map the precise epitope location of the VP3, a phage displayed 12-mer random peptide library was screened by using mAb 3B7. After three rounds of biopanning, 14 phage clones were selected and their reactivity to mAb 3B7 was evaluated (anti-porcine IFN-c mAb as the negative control). Eight clones (1–3, 6, 8, 9, 11, and 12) reacted with mAb 3B7 (OD450 nm, >1.20) but did not react with the anti-porcine IFN-c mAb (OD450 nm, <0.3) (Fig. 3). The other 6 clones were less reactive with mAb 3B7 (OD450 nm, OD < 0.37). Eight phage clones with the high OD values were sequenced and consensus sequence PSNM was found (Table 1).
Sequence alignment showed that this sequence is quite similar to the VP3 region 205 to 208 (205PSNI208) of strain HP-1, but 208I seems different from the putative binding residue 208M for inclusion in the linear epitope. A more reasonable interpretation might be that the Met is selected as an alternative to the Ile at position 208 or perhaps the library itself was biased toward Met. It is necessary to decide whether 208I should be included in this epitope.

Precise amino acids of the epitope. The influence of 208I or 208A or 208M on binding to mAb 3B7 was tested by dot blotting. Dot blotting results showed that the peptide VP3, GST-PSNI, GST-PSNA, and GST-PSNM displayed similar reactivity to mAb 3B7 (Fig. 4), but peptide YIRTPACWD15 (as negative control) and GST-PSN did not show any reaction with 3B7, suggesting that 208I or 208A or 208M is necessary and replicable in this epitope and the 205PSNI208 should be the minimal B-cell epitope of the VP3 protein of DHAV-1.

Table 1. Peptide sequences of the selected phage clones.

| Phage Clone | Sequence |
|-------------|----------|
| 1           | N I G M D Y T P S N I T |
| 2           | S S I H M N V P S N I Q |
| 3           | T A P S P H M P S N A T |
| 6           | Q H M D P Y V P S N M H |
| 8           | H N A N A Q P P S N M M |
| 9           | T G H E S T S P S N A I |
| 11          | H P D A R M I P S N M I |
| 12          | T V F A S A P P S N M Q |
| Consensus   | P S N M |

Sequence alignment showed that this sequence is quite similar to the VP3 region 205 to 208 (205PSNI208) of strain HP-1, but 208I seems different from the putative binding residue 208M for inclusion in the linear epitope. A more reasonable interpretation might be that the Met is selected as an alternative to the Ile at position 208 or perhaps the library itself was biased toward Met. It is necessary to decide whether 208I should be included in this epitope.

Precise amino acids of the epitope. The influence of 208I or 208A or 208M on binding to mAb 3B7 was tested by dot blotting. Dot blotting results showed that the peptide VP3, GST-PSNI, GST-PSNA, and GST-PSNM displayed similar reactivity to mAb 3B7 (Fig. 4), but peptide YIRTPACWD15 (as negative control) and GST-PSN did not show any reaction with 3B7, suggesting that 208I or 208A or 208M is necessary and replicable in this epitope and the 205PSNI208 should be the minimal B-cell epitope of the VP3 protein of DHAV-1.
Epitope sequence analysis among DHAV strains. To determine whether the PSNI epitope is conserved in the VP3 protein among DHAV, we aligned the VP3 epitope region partial sequence with those of other DHAV-1, DHAV-2, and DHAV-3 sequences available in GenBank (Supplementary Table S1). This sequence alignment revealed that all amino acids in the motif region were identical among DHAV-1 strains (Fig. 5) but quite different from DHAV-2 and DHAV-3, indicating that this motif might be a conserved and specific epitope of the VP3 protein of DHAV-1.

Immunological reaction of epitope to duck anti-DHAV-1/-DHAV-3 sera. Dot blotting assay was used to test whether the identified motif PSNI recognized by duck anti-DHAV-1/-DHAV-3 sera. Dot blotting showed that the peptide PSNI and VP3 protein of DHAV-1 were recognized by duck anti-DHAV-1 sera (Fig. 6), but did not react with anti-DHAV-3 sera. Negative control peptide (YIRTPACWD) did not show any reaction to duck anti-DHAV-1 or anti-DHAV-3 sera, indicating that the motif PSNI represented a B-cell epitope of the VP3 protein of DHAV-1. Since anti-DHAV-2 serum is not available, the reactivity of DHAV-2 to this epitope cannot be determined.

Discussion
The use of plasmid DNA as DNA vaccine is a relatively recent approach in the vaccinology field that overcomes many of the problems associated with conventional immunization; for example, the potential danger due to the production and distribution of live vaccine virus. In addition, the proteins expressed by recombinant plasmids are synthesized, processed and presented intracellularly, which is more similar to natural infection than is administration of the conventional vaccine. In this study, to obtain an effective immune response in BALB/c mice, a eukaryotic recombinant plasmid pCI-neo-VP3 as DNA immunogen was successfully constructed, which could synthesize target VP3 protein correctly and efficiently in its native conformation. Three mAbs were prepared and typed using techniques similar to that previously described. Western blot showed that the mAbs...
could specifically react with a 25.5 kDa protein in pCI-neo-VP3 transfected DEF, which was consistent with the expected size of VP3 protein. These results confirmed that pCI-neo-VP3 as DNA immunogen could elicit antibodies against VP3 protein in immunized mice and VP3 protein was successfully expressed in DEF. IFA showed that the VP3 in DHAV-1 infected DEF could also be detected by mAbs, but pCI-neo transfected DEF could not react with mAbs, indicating that mAbs could recognize native VP3 protein of DHAV-1 generated in vivo. IFA and DAPI staining showed that the VP3 protein was located both in the cytoplasm and nucleus of DHAV-1-infected DEF cells, which is consistent with the location of VP3 in FMDV infected cells. Most proteins of RNA viruses enter the nucleus via nuclear localization signals (NLSs), which contain a continuous of basic amino acid residues. When we scanned the VP3 protein sequence, we noticed multiple basic amino acids (’GKRKPCPRPILKPKN’5) at the N-terminal of the VP3 protein. Whether this basic motif serves NLS function needs to be proved.

Well-defined epitopes with mAbs provide a platform for studying antigen structure and developing diagnostic reagents and epitope vaccines. Phage-display and peptide screening have been widely used and offer an attractive approach for the identification of epitopes with mAbs. To our knowledge, there have been no previous reports of the linear epitope mapping of the VP3 of DHAV-1. In this study, we identified a conserved epitope between amino acids 205 and 208 on VP3 protein by using phage display system with mAb 3B7. To confirm the essential amino acid residues (amino acid I208,205PSNI 208) in this epitope region, three designed peptides spanning 205–208 of this epitope coupled with dot blotting analysis demonstrated that motif PSNx is required for mAb 3B7 recognition. Ala or Met selected as an alternative to the ile at position 208 might be that the library itself was biased toward Met or Ala. This motif is identical to the sequence PSNI of the VP3 protein of DHAV-1. Thus, the peptide PSNI is the minimum motif of the epitope needed to retain maximal binding to mAb 3B7. The peptide was also recognized by DHAV-1 positive duck sera, revealing the importance of the four amino acids of the epitope in antibody-epitope binding reactivity and confirming that PSNI is a DHAV-1 serotype-specific epitope. Further experiments are necessary to explore the functional role of this epitope. Sequence alignments of DHAV-1, DHAV-2, and DHAV-3 strains demonstrated that the motif was highly conserved among DHAV-1, but quite different from DHAV-2 and DHAV-3. This finding supports previous reports that there is no cross reactivity between DHAV-1 and DHAV-2 or DHAV-1 and DHAV-3.

Antibody detection assays based on whole antigens with multiple epitopes show greater sensitivity, but cross-reactions are often observed. Epitopes or mimics of natural antigenic determinants, which mainly originate from dominant responses, favor more highly reactive antigens due to their optimized structure or functional properties. Although the minimal epitope identified in this study has only four amino acids in length, it would be useful in the development of discriminating diagnostic kits for DHAV-1, DHAV-2, and DHAV-3 infection. As described previously, in this study, we prepared mAbs and identified motif PSNI as VP3-specific B-cell epitope with neutralizing mAb 3B7. We could speculate that this neutralization activity resulted from correct folding of the VP3 protein. This finding might be valuable in understanding of the antigenic topology of the VP3 of DHAV-1. The strategy by using eukaryotic recombinant plasmid pCI-neo-VP3 as DNA immunogen to prepare mAbs in mice should be widely used for those proteins with expression and purification difficulties.

Methods

Virus and anti-DHAV-1/DHAV-3 sera preparation. DHAV-1 HP-1 and DHAV-3 JT strains were propagated in 10-day-old specific-pathogen free (SPF) embryonated or grown in duck embryo fibroblasts cells (DEF) as described previously. Titters of DHAV-1 HP-1 and DHAV-3 JT are 10^3.5 to 10^4.3 ELD50/0.1 mL, respectively. Post infection duck anti-serum against DHAV-1 HP-1 and DHAV-3 JT were prepared as described previously and used for serological assays.

pCIneo-VP3 construction and transfection in DEF cells. Viral RNA was extracted from DHAV-1 HP-1 by using a viral RNA extraction kit (Qiagen, Shanghai, China). The VP3 encoding gene was amplified using primers F:5′-TAT CTCGAGCCACATGGGAAAGAGA AAACACGCC-3′(the Xho I site is underlined) and R:5′-AAAGCCCGGGTCACTGATTATT GGTTGCCATCTG-3′(the Sma I site is underlined) and then cloned into the eukaryotic expression vector pCI-neo (Clontech) to generate pCI-neo-VP3. The correct orientation of the inserts was confirmed by Xho I and Sma I (New England Biolabs, ON) restriction analysis and nucleotide sequencing. The digested products were analyzed by gel electrophoresis as described previously. Prepared monolayers of DEF cells (approximately 2 × 10^6 cells) were transfected with 6 μg pCI-neo-VP3 or pCI-neo vector as a negative control as described previously. Transfections were done by using Lipofectamine2000 reagent (Invitrogen) according to the manufacturer’s instructions.

VP3-specific mAbs preparation and characterization. Plasmid DNA, pCIneo-VP3 was used as a DNA immunogen for development of mAbs in this study. Briefly, five week old female BALB/c mice were subcutaneously primed with 50 μg of plasmid DNA in sterile phosphate-buffered saline (PBS, pH 7.4). The mice received two boosts of 100 μg of plasmid DNA in sterile PBS twice within a 2-week interval. mAbs were produced using techniques similar to that described previously. The mice were euthanized by anesthesia and the spleens were removed using aseptic techniques. Splenocytes were fused with Sp2/0 myeloma cells at day 3 after the last boosting. After limiting serial dilutions, hybridoma cells binding to VP3 were selected by enzyme-linked immunosorbent assay (ELISA). Hybridoma cell lines secreting antibodies against VP3 were screened and subcloned at least three times by a limiting dilution method and ascitic fluids were prepared with the cloned hybridoma in BALB/C mice. The study was approved by the Committee of the HVRI of the Chinese Academy of Agricultural Sciences, and all mice were used in accordance with guidelines. Isotypes of the produced mAbs were determined by using Mouse Immunoglobulin isotyping kit (Zymed Laboratories, Inc.) according to the manufacturer’s instruction. Virus neutralization test was used to test mAbs neutralizing activity to virus. The test was performed.
using 6-well microplates as described previously. Briefly, 100 μL of serial diluted mAbs were incubated with 100 μL of TCID50 of DHAV-1 for 1.5 h at 37°C. The mixtures were used to inoculate DEF cells. Sera from uninfected healthy mice (diluted in phosphate buffered saline, PBS) and uninfected DEF cells served as controls. Cells were observed daily for cytopathic effects (CPE) for 5 days. Neutralization titers were read as the highest mAb dilution that protected >95% of the cells from CPE.

**Western blot assay.** To examine whether anti-VP3 mAbs recognize the VP3 protein in pCI-neo-VP3 (pCI-neo as negative control) transfected DEF, western blot was used to examine the binding ability of duck anti-DHAV-1 serum or mouse IgG against eukaryotic expressed VP3 proteins. Four days after transfection, collected DEF cells were lysed with RIPA buffer (100 mM Tris–HCl, pH 8.3–8.6, 2% Triton X-100, 150 mM NaCl, 0.6 M KCl, 5 mM EDTA). After centrifugation, the lysate were then subjected to 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with duck anti-DHAV-1 serum followed by a secondary HRP-conjugated goat anti-duck antibody (KPL, MD, USA) or mAbs followed by a secondary HRP-conjugated goat anti-mouse antibody (KPL, MD, USA).

**Immunofluorescence assay.** The immunofluorescence assays were carried out to test mAb specificity to native form of VP3 protein in DHAV-1 HP-1 or DHAV-1 JT strain as described previously. Briefly, monolayers of DEF (approximately 2 × 10^4 cells) grown on coverslips in 6 well plates were infected with DHAV-1 HP-1 (10 M.O.I.) as described previously and then incubated at 37°C for 24 h. After 48 h infection, the infected monolayers or uninfected DEFs (as a negative control) were washed twice with PBS and fixed in methanol at −20°C for 20 min and then probed with different anti-VP3 mAbs (diluted 40×) for 1 h at 37°C. Blocking was carried out in 10% FBS solution at room temperature for 1 h. After washing for three times, the cells were incubated with fluorescent-conjugated Goat anti-Mouse IgG antibody (KPL, MD, USA) (500× dilution). To confirm the location of the VP1 protein, the DEF cells were then stained with DAPI as described previously. Bound antibodies and stained cells were visualized under a fluorescence microscope.

**Epitope mapping.** Isotypes IgG mAb identified by Mouse Immunoglobulin isotyping kit was used for epitope mapping. mAb 3B7 was first purified from mouse ascites fluid using protein G agarose (Invitrogen), according to manufacturer instructions. The concentration of purified IgG was determined by measuring absorbance at 278 nm. The epitope was mapped with purified mAb 3B7 by using the Ph.D-12TM Phage Display Peptide Library Kit (New England BioLabs), as previously described. Three rounds of biopanning were performed to select phage clones. Briefly, each well of a 96-well plate was coated with 10 μg/mL of purified 3B7 and incubated with blocking buffer. The phage library was then added to the plate and incubated for 1 hour. After five washes with PBS buffer, 1 M Tris–HCl was added to the plate to elute the bound phages. The phages were then amplified and titred on LB/IPTG/Xgal plates for selection.

**ELISA and sequencing of phage clones.** After three rounds of biopanning, as described above and elsewhere, individual phage clones were selected for target binding in an ELISA. Briefly, 96-well plates were coated with 100 ng of mAbs or mouse anti–porcine IFN-γ (Sigma-Aldrich) as a negative control. The coated wells were then blocked, and the selected phages were added. The coated plates were then washed ten times with TBST, and bound phages were detected with horse radish peroxidase (HRP)-conjugated sheep anti–M13 antibody (Pharmacia), as described previously. Color development was achieved by adding a substrate solution containing o-phenylenediamine. Positive phage clones were sequenced with M13 primer.

**Sequence analysis.** To assess the level of conservation of the epitope among DHAV-1, DHAV-2, and DHAV-3, we performed sequence alignments of the epitope corresponding locations in the VP3 protein of DHAV strains using Lasergene software (DNASTAR). Representative DHAV-1, DHAV-2, and DHAV-3 virus information used in sequence analyses was listed in Table S1.

**Minimal epitope identification and epitope cross-reactivity to DHAV-1-/DHAV-3-positive serum.** To define the fourth amino acid x in PSNx, four GST-tagged peptides PSN, PSNI, PSNA, PSNM spanning 205–208 amino acids of VP3 were synthesized (with purity >95%). Briefly, complementary oligonucleotide primers that were specific for each peptide fragments were designed as previously described. Nucleotide segments with sticky ends were produced by XhoI/SmaI digestion and direct annealing. The oligonucleotide fragments were then cloned into the pGEX6p-1 vector (GE Healthcare). The expressed peptides were purified using a GST Purification Kit (Takara). Dot blotting assay was performed to identify the minimal epitope and epitope peptide cross-reactivity to DHAV-1-/DHAV-3-positive serum. Briefly, approximately 1 μg of each synthesized peptide or epitope peptide diluted with TNE buffer was spotted onto the nitrocellulose membrane (Millipore) and incubated with 3B7 (diluted 1:1000 in PBS) or with DHAV-1-/DHAV-3 serum (1:200 in PBS) at 37°C for 1 hour. After washing the three times with PBS, the membrane was probed with blocking buffer. The coated plates were then washed ten times with TBST, and bound phages were detected with horse radish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:500 dilution, KPL) or HRP-conjugated goat anti- antibody IgG (1:500 dilution, KPL) at 37°C for 1 hour. Peptide 3B7PACWD and VP3 protein were used as negative and positive control, respectively.

**References**

1. Kim, M. C. et al. Molecular analysis of duck hepatitis virus type 1 reveals a novel lineage close to the genus Parvoviridae in the family Picornaviridae. *J Gen Virol.* 87(11), 3307–3316 (2006).
2. Tseng, C. H., Knowles, N. J. & Tsai, H. J. Molecular analysis of duck hepatitis virus type 1 indicates that it should be assigned to a new genus. *Virus Res.* 123, 190–203 (2007).
3. Tseng, C. H. & Tsai, H. J. Molecular characterization of a new serotype of duck hepatitis virus. *Virus Res.* **126**(1–2), 19–31 (2007).
4. Kim, M. C. *et al.* Recent Korean isolates of duck hepatitis virus reveal the presence of a new geno- and sero type when compared to duck hepatitis virus type 1 type strains. *Arch Virol.* **152**(3), 2059–2072 (2007).
5. Liu, M., Li, X. J., Zhang, Z., Liu, S. & Zhang, Y. Goose haemorrhagic hepatitis caused by a new subtype duck hepatitis virus type 1 virus. *Vet Microbio.* **152**(3), 280–283 (2011).
6. Kim, M. C., Kwon, Y. K., Joo, S. J., Kwon, J. H. & Lindberg, M. A. Differential diagnosis between type-specific duck hepatitis virus type 1 (DHV-1) and recent Korean DHV-1-like isolates using a multiplex polymerase chain reaction. *Avian Pathol.* **37**(2), 171–177 (2008).
7. Woolcock, P. R. Duck hepatitis. In: Diseases of Poultry, 11th ed. Iowa State Press, Iowa, pp. 343–354(2003).
8. Pulli, T., Lankinen, H., Rovainen, M. & Hyytipa, T. Antigenic sites of coxsackievirus A9. *Virology* **240**, 202–212 (1999).
9. Oberste, M. S., Maher, K., Kilpatrick, D. R. & Pallansch, M. A. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. *J Virol.* **73**, 1941–1948 (1999).
10. Liu, M. *et al.* Development and evaluation of a VP1-ELISA for detection of antibodies to duck hepatitis type 1 virus. *J Virological Meth.* **169**, 66–69 (2010).
11. Li, X. J. *et al.* Evidence of VP1 of duck hepatitis A virus type 1 as a target of neutralizing antibodies and involving receptor-binding activity. *Virus Res.* **227**, 240–244 (2017).
12. Wu, X. Y. *et al.* Identification of a Conserved B-Cell Epitope on Duck Hepatitis A Type 1 Virus VP1 Protein. *PLoS ONE** **10**(2), e0118041 (2015).
13. Sa-Carvalho, D. *et al.* Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. *J Virol.* **71**, 5115–5123 (1997).
14. Borca, M. V. *et al.* Role of arginine-56 within the structural protein VP3 of foot-and-mouth disease virus (FMDV) O1 Campos in virus virulence. *Virology* **422**, 37–45 (2012).
15. Li, Y. F. *et al.* Antigenic analysis monoclonal antibodies against different epitopes of β protein of Muscovy duck reovirus. *Virus Research* **163**, 546–551 (2012).
16. Cedillo-Barro, L., Foster-Cuevas, M., Belsham, G. J., Le Févre, F. R. & Parkhouse, M. E. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. *J Gen Virol.* **82**, 1713–1724 (2001).
17. Zhang, T. T. *et al.* Characterization of monoclonal antibodies against duck hepatitis type1 virus VP1 protein. *J Virological Meth.* **208**, 166–170 (2014).
18. Yin, X. C. *et al.* Characterization of monoclonal antibodies 3 against waterfowl parvoviruses VP3 protein. *Virology J.* **9**, 288 (2012).
19. Liu, M. *et al.* Characterization of monoclonal antibodies against Muscovy duck reovirus VP3 protein. *Virology J.* **7**, 133 (2010).
20. Li, D. *et al.* Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-γ signal transduction pathways. *Cell Cycle* **15**(6), 850–860 (2016).
21. Guo, D. C. *et al.* Muscovy duck reovirus p10.8 protein localizes to the nucleus via a nonconventional nuclear localization signal. *Virology J.* **11**, 37 (2014).
22. Dingwall, C. & Laskey, R. A. Nuclear targeting sequences—a consensus? *Trends Biochem Sci.* **16**, 478–481 (1991).
23. Dworetzky, S. I., Lanford, R. E. & Feldherr, C. M. The effects of variations in the number and sequence of targeting signals on nuclear uptake. *J Cell Biol.* **107**, 1279–1287 (1988).
24. Alain, C. T. *et al.* Versatile virus-like particle carrier for epitope based vaccines. *PLoS ONE* **5**, e09809 (2010).
25. Li, C. X. *et al.* Epitope Identification and Application for Diagnosis of Duck Tebemus Virus Infections in Ducks. *Viruses* **8**, 306 (2016).
26. Wu, H. C. *et al.* Identification of B-Cell Epitope of Dengue Virus Type 1 and Its Application in Diagnosis of Patients. *J Clin Microbio.* **39**, 977–982 (2001).
27. Woolcock, P. R. An assay for duck hepatitis virus type I in duck embryo liver cells and a comparison with other assays. *Avian Pathol.* **15**, 75–82 (1986).
28. Li, C. X. *et al.* A New Broadly Cross-reactive Epitope within Domain III Identified with Monoclonal Antibody against E Protein of Duck Tebemus Virus. *Scientific Reports* **6**, 36288 (2016).
29. Li, C. X. *et al.* A Conserved Epitope Mapped with a Monoclonal Antibody against the VP3 Protein of Goose Parvovirus by Using Peptide Screening and Phage Display Approaches. *PLoS ONE* **11**(5), e0147961 (2016).
30. Burland, T. G. DNASTAR’s Lasergene sequence analysis software. *Meth Mol Biol.* **132**, 71–91 (2000).

Acknowledgements
This study was supported by National Key R & D Program (2016YFDD0500100), the Natural Science Foundation of China (31670153), and CAAS-XTCX2016011-04-9. Yun Zhang supervised and provided the funding for the study.

Author Contributions
M.L. and Y.Z. designed the study. T.L., D.G. and F.M. did plasmid construction and prepared mAbs. X.W. and C.L. identified epitope. X.Y., W.S. and Q.Z. analyzed the data. M.L., C.L. and Y.Z. wrote the paper.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10909-7

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017